TRX 214
Alternative Names: TRX-214; TRX-214-1002Latest Information Update: 17 Jun 2025
At a glance
- Originator Therapex
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Peptide-chain-release factor 3 degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 25 Apr 2025 Preclinical trials in Acute myeloid leukaemia in South Korea (unspecified route) prior to April 2025
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from a preclinical study in Acute myeloid leukaemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 18 Dec 2023 Early research in Cancer in South Korea (unspecified route), prior to December 2023 (Therapex pipeline, December 2023)